US Generic Drug Market Share, Size Trends and Forecast 2017-2022

1

US Generic Drugs Market Global Industry Trends,
Share, Size, Growth, Opportunity and Forecast
2017-2022
Copyright IMARC. All Rights Reserved
2
About IMARC Group
Report Description
IMARC is a leading advisor on management
strategy and market research worldwide. We
partner with clients in all sectors and regions
to identify their highest-value opportunities,
address their most critical challenges, and
transform their businesses. IMARCs information
products include major market, scientific,
economic and technological developments for
business leaders in pharmaceutical, industrial,
and high technology organizations. Market
forecasts and industry analysis for
biotechnology, advanced materials,
pharmaceuticals, food and beverage, travel and
tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
The US Generic Drugs Market Catalysed by
Patent Expiry of Branded Drugs Generic drugs are
bioequivalents and offer the same benefits and
drawback as the branded drugs, at an affordable
price. The US generic drug market has witnessed a
significant growth in recent years, driven
primarily owing to the patent expiry of branded
drugs. The United States represents the worlds
biggest and most important market for
pharmaceuticals and around 80 of the
prescription drugs consist of generic drugs.
These drugs are bioequivalent they offer the
same dosage, strength, quality, form, effect,
intended use, side effects, route of
administration, therapeutic effect, etc., as
their branded counterparts. This helps in
assuring that the medicines are safe and
effective for the consumers. The latest report by
IMARC Group, US Generic Drug Market Industry
Trends, Share, Size, Growth, Opportunity and
Forecast 2017-2022, finds that the US generic
drug market has grown at a CAGR of more than 13
during 2010-2016, reaching a sales volume of more
than 4000 Million prescriptions. Request Sample
of the Report _at_ http//www.imarcgroup.com/request?
typereportid567flagB
4
Report Description and Highlights
Report Description
5
Report Description and Highlights
Report Description

• Highlights of the US generic drug market
• Generic drugs are bioequivalents and can be
  obtained at cheaper prices.
• In the US, the market is growing as a result of
  patent expiry of branded drugs.
• Teva represents the largest generic manufacturer
  in the US.
•  
• One of the major factors that has contributed to
  the growth of this market is the patent expiry of
  a number of blockbuster branded drugs. Once
  branded drugs go off-patent, manufacturers can
  launch generic versions of these drugs. As these
  drugs have low research development
  requirements, the costs involved in developing
  and manufacturing them are significantly lower
  than branded drugs. This allows generic
  manufacturers to price their drugs considerably
  lower compared to branded drugs. This has
  ultimately enabled the government, third-party
  payers and patients to save billions of dollars
  on healthcare expenditures. Other growth inducing
  factors include aging population, increasing
  prevalence of chronic diseases, and incentives
  offered to physicians and pharmacists to promote
  generics.
• Read full Report _at_ http//www.imarcgroup.com/us-ge
  nerics-market

6
Report Description and Highlights
Report Description
The market for generic drugs is segmented on the
basis of branded and unbranded generics.
Currently, unbranded generic drugs dominate the
market, accounting for the majority of the total
generic prescription volumes. On the basis of
distribution, some of the key purchasers include
Red Oak Sourcing, Walgreens Boots Alliance,
McKesson One Stop, Econdisc Contracting
Solutions, etc. Furthermore, an analysis of the
competitive landscape finds that Teva represents
the largest generic manufacturer in the US
accounting for around a fifth of the total
generic sales. The other players operative in the
market include Mylan Labs Inc., Sandoz, Endo/Par,
Sun Pharmaceutical, Actavis, Par Pharmaceuticals,
Lupin Pharmaceuticals, Dr Reddys and
Hospira. The report provides a comprehensive
insight into the historical and current trends as
well as the future prospects of the generic drug
market in the United States. This study serves as
an exceptional tool to understand the sales
trends, volume trends, growth, key segments,
competitive structure, regulations, major
manufacturer, major distributors, top drugs,
manufacturing requirements, opportunities and
future prospects of the US generic drug market.
This report can serve as an excellent guide for
manufacturers, consultants, researchers,
marketing strategists and all those who plan to
foray into the US generic drug market in any
form. Browse more reports related to healthcare
industry _at_ http//www.imarcgroup.com/categories/h
ealthcare-market-research-reports

7
Report Description and Highlights
Report Description

2017 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
8

Contact Us